Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain
  • Bernadene Fernandopulle
    Launceston General Hospital, Tasmania, Australia
  • Terry Brain
    Launceston General Hospital, Tasmania, Australia

Abstract

No Abstract Available

Keywords

Intermediate, high-risk MDS; IPSS; lenalidomide; hematological response; dose-modified.

Full Text:

PDF
HTML
Submitted: 2014-06-11 12:31:25
Published: 2010-05-31 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
238

Views:
PDF
88
HTML
197

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Comments on this article

View all comments


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185